Chemiluminescence Immunoassay Market Size, Share and Growth Outlook, 2026

Chemiluminescence Immunoassay Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Chemiluminescence Immunoassay Market size is forecast to increase from $16.6 Billion in 2026 to $30.5 Billion in 2034 at a CAGR of 7.9% between 2026 and 2034.

The Chemiluminescence Immunoassay market report provides detailed analysis and outlook of Chemiluminescence Immunoassay segments including By Product Type (Instruments, Reagents, Consumables and Accessories), By Technology Platform (Chemiluminescence Enzyme Immunoassay, Electrochemiluminescence Immunoassay, Microparticle Chemiluminescence Immunoassay ), By Sample Type (Blood Samples, Urine Samples, Saliva Samples, Other Body Fluids), By Application (Infectious Disease Testing, Oncology, Endocrinology and Hormonal Panels, Cardiology and Metabolic Biomarkers, Autoimmune Disorders, Therapeutic Drug Monitoring ), By End-User (Central and Reference Clinical Laboratories, Hospitals and Healthcare Networks, Pharmaceutical and Biotech Industries, Academic Research Organizations) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Chemiluminescence Immunoassay Industry Overview

Automated Hormone Testing Expanding Clinical Diagnostic Capabilities

The Chemiluminescence Immunoassay industry continues to grow as laboratories increasingly adopt automated testing platforms capable of delivering rapid, highly sensitive diagnostic results. A significant advancement was achieved when Revvity, through its Immunodiagnostic Systems subsidiary, received U.S. FDA 510(k) clearance for its Total Testosterone automated Chemiluminescence Immunoassay. Designed to operate on the company's proprietary random-access testing systems, the assay complements previously cleared chemiluminescence-based tests for Free Testosterone and Sex Hormone-Binding Globulin. Together, these assays create a comprehensive single-platform workflow that supports the evaluation of suspected male hypogonadism and related endocrine disorders. By consolidating hormone testing onto an automated immunoassay platform, clinical laboratories can reduce reliance on complex liquid chromatography-mass spectrometry calculations while improving workflow efficiency, turnaround times, and diagnostic consistency.

Laboratory Automation Driving Operational Efficiency

Automation remains a major growth driver within the chemiluminescence immunoassay market as healthcare facilities seek to increase testing throughput while minimizing manual intervention. At the China Association of Clinical Laboratory Practice exhibition, Getein Biotech introduced the MAGICL 6800 Fully Automated Chemiluminescence Immunoassay Analyzer. The system is specifically engineered for clinical laboratories and urgent care environments requiring high-volume diagnostic processing. A distinguishing feature is its integrated hematocrit measurement module, which enables direct analysis of whole-blood samples without the need for manual centrifugation. The analyzer automatically calculates serum-equivalent values while independently managing decapping and recapping procedures, significantly reducing laboratory workload. These innovations enhance operational efficiency, improve sample handling accuracy, and support the growing demand for streamlined diagnostic workflows in modern healthcare settings.

Infectious Disease Testing Strengthening Chemiluminescent Platforms

Chemiluminescence immunoassays are also playing an increasingly important role in infectious disease diagnostics due to their sensitivity, automation compatibility, and scalability. A notable example is the FDA premarket notification approval granted to Beckman Coulter for its Access anti-HAV IgM assay. The test utilizes paramagnetic-particle chemiluminescent immunoassay technology to qualitatively detect Immunoglobulin M antibodies against the Hepatitis A virus in human serum or plasma samples. The automated assay employs a chemiluminescent substrate within specialized reaction vessels, generating relative light unit measurements that are interpreted through an integrated luminometer and calibration system. This highly automated testing approach improves laboratory efficiency while supporting rapid and reliable detection of acute Hepatitis A infections. As healthcare systems continue to emphasize early disease identification and high-throughput diagnostic capacity, chemiluminescence immunoassays remain a critical technology platform across endocrine, infectious disease, oncology, and clinical chemistry applications.

Chemiluminescence Immunoassay Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Chemiluminescence Immunoassay market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Roche Diagnostics, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation (Beckman Coulter), DiaSorin S.p.A., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Sysmex Corporation, BioMérieux SA, QuidelOrtho Corporation, Thermo Fisher Scientific Inc.. The Chemiluminescence Immunoassay market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Chemiluminescence Immunoassay industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Chemiluminescence Immunoassay Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Chemiluminescence Immunoassay companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Chemiluminescence Immunoassay markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Chemiluminescence Immunoassay Market Competitive Benchmarking and Company Analysis

Leading companies in Chemiluminescence Immunoassay industry include- Roche Diagnostics, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation (Beckman Coulter), DiaSorin S.p.A., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Sysmex Corporation, BioMérieux SA, QuidelOrtho Corporation, Thermo Fisher Scientific Inc.. The Chemiluminescence Immunoassay market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Chemiluminescence Immunoassay Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Chemiluminescence Immunoassay market remains one of the strongest-performing segments in the country.
The US Chemiluminescence Immunoassay Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Chemiluminescence Immunoassay market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Chemiluminescence Immunoassay industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Chemiluminescence Immunoassay markets

Canada's strong Chemiluminescence Immunoassay sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Chemiluminescence Immunoassay market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Chemiluminescence Immunoassay Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Chemiluminescence Immunoassay market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Chemiluminescence Immunoassay population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Chemiluminescence Immunoassay industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Chemiluminescence Immunoassay market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Chemiluminescence Immunoassay sales through 2034

France Chemiluminescence Immunoassay companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Chemiluminescence Immunoassay Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Chemiluminescence Immunoassay distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Chemiluminescence Immunoassay Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Chemiluminescence Immunoassay market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Chemiluminescence Immunoassay industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Chemiluminescence Immunoassay industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Chemiluminescence Immunoassay Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Chemiluminescence Immunoassay market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Chemiluminescence Immunoassay market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Chemiluminescence Immunoassay Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Chemiluminescence Immunoassay Market Segmentation

By Product Type
Instruments
Reagents
Consumables and Accessories
By Technology Platform
Chemiluminescence Enzyme Immunoassay
Electrochemiluminescence Immunoassay
Microparticle Chemiluminescence Immunoassay
By Sample Type
Blood Samples
Urine Samples
Saliva Samples
Other Body Fluids
By Application
Infectious Disease Testing
Oncology
Endocrinology and Hormonal Panels
Cardiology and Metabolic Biomarkers
Autoimmune Disorders
Therapeutic Drug Monitoring
By End-User
Central and Reference Clinical Laboratories
Hospitals and Healthcare Networks
Pharmaceutical and Biotech Industries
Academic Research Organizations

Top Companies in Chemiluminescence Immunoassay Industry

Roche Diagnostics
Abbott Laboratories
Siemens Healthineers AG
Danaher Corporation (Beckman Coulter)
DiaSorin S.p.A.
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Sysmex Corporation
BioMérieux SA
QuidelOrtho Corporation
Thermo Fisher Scientific Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025